GAP’s statement: Study cites limited awareness among patients and physicians, anxiety, and lack of quick diagnostics Washington, DC (August 20, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding a University of Southern California Louis D. Schaeffer Center for Health Policy & Economics white paper, “Key Barriers to […]
Washington D.C. (July 30, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding recent groundbreaking advances in Alzheimer’s blood test research: “I want to congratulate and thank Dr. Barthélemy, Dr. Horie, Dr. Sato, Dr. Bateman, Dr. Palmqvist, Dr. Janelidze, and Dr. Quiroz on their published research on two […]
Washington D.C. (July 9, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding Biogen’s submission of its BLA application for Aducanumab with the FDA: “The Alzheimer’s research community is looking forward to a thoughtful review of Aducanumab and ideally, approval by the FDA. This application represents a singular […]
June 2, 2020 The events that spurred the reaction around the country this weekend are painful reminders that injustice remains in our world. At the Global Alzheimer’s Platform Foundation® (GAP), we agree that monumental changes on local and national levels are necessary to address the issues plaguing Black and African American people in our country […]
At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]
Three research volunteers given first ever national award for their essential role in combatting the greatest public health crisis for our society in this century Washington, DC (October 23, 2019) – Today, the Global Alzheimer’s Platform Foundation® (GAP) honors three Citizen Scientists® in recognition of the indispensable role clinical trial volunteers play in the fight […]
First disease-modifying drug in 16 years to be submitted for FDA approval in 2020 ***John Dwyer is available for comment today live from the National Alzheimer’s Summit in Washington, D.C.*** Washington, DC (October 22, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement on the announcement today […]
Spartan will donate $5 to the GAP Transportation Program from each sale of its rapid APOE test to GAP-Net Research Sites Ottawa, Canada (July 31, 2019) – Spartan Bioscience today announced a partnership with the Global Alzheimer’s Platform Foundation® (GAP) to help recruit possible study participants and accelerate Alzheimer’s clinical trials. Through the partnership, Spartan will donate $5 from […]
During National Citizen Scientist Week, June 17-21, GAP Honors More Than 100 Award Nominees Washington, DC (June 17, 2019) – June 17-21, 2019 is the first ever National Citizen Scientist Week, a time to honor people who volunteer for Alzheimer’s research and inspire hope for new therapies for the disease. To celebrate the contributions of the remarkable volunteers […]
NIA Makes $9 Million Multiyear Grant to Study New Therapeutic Approach, an Orally- Administered Treatment for Alzheimer’s Washington, DC (May 20, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The nearly six million Americans with Alzheimer’s and their families deserve for no scientific stone to go […]